Relay Therapeutics: Revitalized By Breast Cancer Program, But Competition Is Intense
Relay Therapeutics Inc RLAY
$18.83
▼ -3.19%
($-0.62)
🔥 High Short Interest
📅 Earnings This Week
Open
$19.76
Prev Close
$19.45
Day Range
$18.45 – $19.76
52W Range
$3.03 – $20.79
Market Cap
$4.10B
Beta
1.66
EPS (TTM)
$-1.57
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-07-16 |
| Shares Out. | 215,560,000 |
| Website | relaytx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 192 |
| Revenue | $3.0M |
| Gross Profit | $3.0M |
| Net Income | -$73.3M |
| Free Cash Flow | -$213.4M |
| Total Assets | $699.6M |
| Total Liabilities | $57.4M |
| Equity | $642.2M |
About Relay Therapeutics Inc
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics Inc is a publicly traded company under the ticker symbol RLAY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)